{"entity":{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Enzalutamide in prostate cancer, run by Syntrix Biosystems, Inc., now recruiting.","summary":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer is a phase 2 interventional study registered as NCT06228053 by Syntrix Biosystems, Inc., with 53 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-06-30. Interventions recorded: SX-682, Enzalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06228053","url":"https://clinicaltrials.gov/study/NCT06228053"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["enzalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06228053","phase":"2","setting":"A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial","sponsor":"Syntrix Biosystems, Inc.","enrolled":53,"outcomes":[]},"route":"/trials/nct06228053/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}]}}